ESMO 2024 | Advances in immunotherapy for head and neck squamous cell carcinoma
Luigi Lorini, MD, Humanitas Research Hospital, Rozzano, Italy, discusses the evolving treatment landscape for head and neck squamous cell carcinoma (HNSCC), emphasizing the promising results of immunotherapy, particularly in recurrent disease and neoadjuvant settings. Ongoing trials explore the use of immunotherapy in combination with surgery, radiotherapy, and adjuvant treatments. The future may involve intra-tumoral approaches combined with systemic therapies to enhance efficacy and minimize toxicity, with biomarker-driven patient selection becoming crucial for optimizing outcomes. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
